Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
Status
Conditions
Treatments
Details and patient eligibility
About
The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.
Full description
The investigators intend to test Epstein-Barr virus antibodies (Viral Capsid Antigen-immunoglobulin A， Epstein-Barr nuclear antigen 1-immunoglobulin A， early antigen-immunoglobulin A， Zta-immunoglobulin A， Rta-immunoglobulin G, Bnlf 2b) by ELISA and Epstein-Barr virus DNA by quantitative polymerase chain reaction, target sequencing and CRISPR-associated protein 12a in nasopharyngeal brushing and plasma of the same population at high-risk of nasopharyngeal carcinoma so as to determine the best method in nasopharyngeal carcinoma screening.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- residents in Southern China
- 30-62 years old
- male
- a first-degree relative of at least one nasopharyngeal carcinoma patient
- no medical record of nasopharyngeal carcinoma
- Eastern Cooperative Oncology Group score of 0-2
- be able to comprehend, sign, and date the written informed consent document to participate in the study
Exclusion criteria
- history of nasopharyngeal carcinoma
- heavy cardiovascular, liver or kidney disease
- on systemic steroid or immunosuppressant treatment or active autoimmune disease
Trial design
11,625 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Ming-Yuan Chen, MD, PhD; Si-Yuan Chen, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal